Mineralys Therapeutics, Inc. MLYS
16.19 USD -0.81 (-4.76%)
Nov 5, 2026, 10:18 AM EST
15.84 Day range 17.66
15.33 52-week range 47.65
- YTD
- -55.39%
- 1 year
- -59.17%
Financial health
Altman Z-Score
4.54 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
1 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C2 / 5 overall
- DCF 2
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 3
- P/E 1
- P/B 2
Valuation
P/E -15.8×
FY 2020 5y median -4.3× FY 2025
P/S 0.0×
FY 2020 5y median 0.0× FY 2025
P/B 3.8×
FY 2020 5y median 1.3× FY 2025
P/FCF -17.2×
FY 2020 5y median -3.8× FY 2025
EV/EBITDA -14.8×
FY 2020 5y median -3.6× FY 2025
EV/Sales 0.0×
FY 2020 5y median 0.0× FY 2025
FCF Yield -5.8%
FY 2020 5y median -26.1% FY 2025
Profitability
Gross Margin 0.0%
FY 2020 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2020 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2020 5y median 0.0% FY 2025
ROE -23.9%
FY 2020 5y median -23.9% FY 2025
ROIC -26.4%
FY 2020 5y median -35.1% FY 2025
ROA -23.4%
FY 2020 5y median -28.6% FY 2025
Growth (YoY)
Revenue 0.0%
FY 2020 FY 2025
Operating Income 11.3%
FY 2020 FY 2025
EPS (diluted) 37.4%
FY 2020 FY 2025
Free Cash Flow 14.4%
FY 2020 FY 2025
Financial Health
Current Ratio 43.8×
FY 2020 5y median 14.0× FY 2025
Quick Ratio 43.8×
FY 2020 5y median 14.0× FY 2025
Debt / Equity 0.0×
FY 2020 5y median 0.0× FY 2025
Net Debt / EBITDA 1.1×
FY 2020 5y median 0.7× FY 2025
Interest Coverage 0.0×
FY 2020 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2020 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2020 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31